The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

Study results show that genetic sensitivity to stress was linked to a 49% higher risk of lung cancer in people of European ...

Nuvectis is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

Paul Nghiem, MD, PhD, and the Nghiem Lab have championed innovations in MCC treatment, delivering new treatment options, ...

Scientists have found a molecular switch that reverses cancer cells in the body back to their normal, healthy state.

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

Professor Kwang-Hyun Cho's research team has recently been highlighted for their work on developing an original technology ...

Five students from Ouachita Baptist University’s Patterson School of Natural Sciences have published research in the ...

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...